{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T21:21:57Z","timestamp":1792963317911,"version":"4.5.0"},"reference-count":32,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Allergan Aesthetics, an AbbVie Company"},{"name":"Peloton Advantage, LLC. (an OPEN Health company)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>TrenibotulinumtoxinE (trenibotE), a botulinum neurotoxin serotype E (BoNT\/E), is being developed for clinical use, and can fill a unique treatment gap for patients who are seeking neurotoxin treatment with a rapid onset and short duration of effect. This preclinical study characterized the pharmacological activity of trenibotE using the mouse Digit Abduction Score (DAS) assay. A comparative analysis was also performed between trenibotE and an equi-efficacious dose of the botulinum neurotoxin serotype A (BoNT\/A) onabotulinumtoxinA (onabotA). TrenibotE showed a dose-dependent increase in peak DAS and duration of effect. A comparison of onabotA and trenibotE in this assay at approximate equi-efficacious doses showed trenibotE to have a faster onset of effect (trenibotE yielded a significantly greater effect as early as 6 h post-injection), shorter time to peak effect (24\u201327 h vs. 2 days), and an overall shorter duration of response (3 days vs. 14 days). The unique temporal characteristics of trenibotE and pharmacological differentiation from onabotA observed in this preclinical assay support the clinical development of this molecule.<\/jats:p>","DOI":"10.3390\/toxins17050230","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T04:28:22Z","timestamp":1746505702000},"page":"230","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Preclinical Evaluation of Botulinum Toxin Type E (TrenibotulinumtoxinE) Using the Mouse Digit Abduction Score (DAS) Assay"],"prefix":"10.3390","volume":"17","author":[{"given":"Gregory S.","family":"Nicholson","sequence":"first","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Canty","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie","family":"Southern","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Whelan","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy D.","family":"Brideau-Andersen","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron S.","family":"Broide","sequence":"additional","affiliation":[{"name":"Allergan Aesthetics, an AbbVie Company, Irvine, CA 92612, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1124\/pr.116.012658","article-title":"Botulinum neurotoxins: Biology, pharmacology, and toxicology","volume":"69","author":"Pirazzini","year":"2017","journal-title":"Pharmacol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Benedetto, A.V. (2017). Botulinum toxins: Pharmacology, immunology, and current developments. Botulinum Toxins in Clinical Aesthetic Practice, CRC Press. [3rd ed.].","DOI":"10.1201\/9780203729755"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Ko\u0161enina, S., Mart\u00ednez-Carranza, M., Davies, J.R., Masuyer, G., and Stenmark, P. (2021). Structural analysis of botulinum neurotoxins type B and E by cryo-EM. Toxins, 14.","DOI":"10.3390\/toxins14010014"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.toxicon.2013.05.004","article-title":"The rat Digit Abduction Score (DAS) assay: A physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis","volume":"71","author":"Broide","year":"2013","journal-title":"Toxicon"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2147\/CCID.S397999","article-title":"A preclinical study comparing the activity and potency of onabotulinumtoxinA and prabotulinumtoxinA","volume":"16","author":"Rupp","year":"2023","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1097\/DSS.0000000000000626","article-title":"Efficacy and safety of onabotulinumtoxinA treatment of forehead lines: A multicenter, randomized, dose-ranging controlled trial","volume":"42","author":"Solish","year":"2016","journal-title":"Dermatol. Surg."},{"key":"ref_7","first-page":"461","article-title":"A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides","volume":"29","author":"Carruthers","year":"2003","journal-title":"Dermatol. Surg."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.toxicon.2014.07.009","article-title":"Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: A 20-year follow-up","volume":"90","author":"Jankovic","year":"2014","journal-title":"Toxicon"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Brin, M.F., Nelson, M., Ashourian, N., Brideau-Andersen, A., and Maltman, J. (2024). Update on non-interchangeability of botulinum neurotoxin products. Toxins, 16.","DOI":"10.3390\/toxins16060266"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0304-3940(98)00775-7","article-title":"Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans","volume":"256","author":"Eleopra","year":"1998","journal-title":"Neurosci. Lett."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Tehran, D.A., and Pirazzini, M. (2018). Novel botulinum neurotoxins: Exploring underneath the iceberg tip. Toxins, 10.","DOI":"10.3390\/toxins10050190"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/S1044-7431(02)00016-7","article-title":"Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: The extent and duration are dictated by the sites of SNAP-25 truncation","volume":"22","author":"Meunier","year":"2003","journal-title":"Mol. Cell. Neurosci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0041-0101(00)00120-3","article-title":"Persistence of botulinum neurotoxin A demonstrated by sequential administration of serotypes A and E in rat EDL muscle","volume":"39","author":"Adler","year":"2001","journal-title":"Toxicon"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e00446","DOI":"10.1002\/prp2.446","article-title":"A comparison of biological activity of commercially available purified native botulinum neurotoxin serotypes A1 to F1 in vitro, ex vivo, and in vivo","volume":"6","author":"Donald","year":"2018","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Martin, V., Carre, D., Bilbault, H., Oster, S., Limana, L., Sebal, F., Favre-Guilmard, C., Kalinichev, M., Leveque, C., and Boulifard, V. (2024). Intramuscular botulinum neurotoxin serotypes E and A elicit distinct effects on SNAP25 protein fragments, muscular histology, spread and neuronal transport: An integrated histology-based study in the rat. Toxins, 16.","DOI":"10.3390\/toxins16050225"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Rupp, D., Nicholson, G., Canty, D., Wang, J., Rh\u00e9aume, C., Le, L., Steward, L.E., Washburn, M., Jacky, B.P., and Broide, R.S. (2020). OnabotulinumtoxinA displays greater biological activity compared to incobotulinumtoxinA, demonstrating non-interchangeability in both in vitro and in vivo assays. Toxins, 12.","DOI":"10.3390\/toxins12060393"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"s3","DOI":"10.1111\/j.1468-1331.1999.tb00032.x","article-title":"Preclinical update on BOTOX (botulinum toxin type A)-purified neurotoxin complex relative to other botulinurn neurotoxin preparations","volume":"6","author":"Aoki","year":"1999","journal-title":"Eur. J. Neurol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"847e","DOI":"10.1097\/PRS.0000000000005029","article-title":"Safety and efficacy of EB-001, a novel type E botulinum toxin, in subjects with glabellar frown lines: Results of a phase 2, randomized, placebo-controlled, ascending-dose study","volume":"142","author":"Yoelin","year":"2018","journal-title":"Plast. Reconstr. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jmb.2008.12.027","article-title":"Domain organization in Clostridium botulinum neurotoxin type E is unique: Its implication in faster translocation","volume":"386","author":"Kumaran","year":"2009","journal-title":"J. Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1038\/s41467-023-37860-8","article-title":"Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2","volume":"14","author":"Liu","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Gardner, A.P., and Barbieri, J.T. (2018). Light chain diversity among the botulinum neurotoxins. Toxins, 10.","DOI":"10.3390\/toxins10070268"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3208","DOI":"10.1073\/pnas.0400229101","article-title":"Plasma membrane localization signals in the light chain of botulinum neurotoxin","volume":"101","author":"Steward","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0928-4257(98)80151-4","article-title":"On the action of botulinum neurotoxins A and E at cholinergic terminals","volume":"92","author":"Washbourne","year":"1998","journal-title":"J. Physiol. Paris."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.coph.2004.12.006","article-title":"Botulinal neurotoxins: Revival of an old killer","volume":"5","author":"Montecucco","year":"2005","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.tibs.2005.05.002","article-title":"SNARE complexes and neuroexocytosis: How many, how close?","volume":"30","author":"Montecucco","year":"2005","journal-title":"Trends Biochem. Sci."},{"key":"ref_26","first-page":"3294","article-title":"Recruitment of septin cytoskeletal proteins by botulinum toxin A protease determines its remarkable stability","volume":"127 Pt 15","author":"Vagin","year":"2014","journal-title":"J. Cell Sci."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"E5158","DOI":"10.1073\/pnas.1621076114","article-title":"Deubiquitinating enzyme VCIP135 dictates the duration of botulinum neurotoxin type A intoxication","volume":"114","author":"Tsai","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_28","first-page":"tre-02-85-417-411","article-title":"Diffusion of botulinum toxins","volume":"2","author":"Brodsky","year":"2012","journal-title":"Tremor Other Hyperkinet. Mov."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.toxicon.2022.04.003","article-title":"The distribution of neuromuscular junctions depends on muscle pennation, when botulinum neurotoxin receptors and SNAREs expression are uniform in the rat","volume":"212","author":"Martin","year":"2022","journal-title":"Toxicon"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s12565-012-0169-3","article-title":"Investigation of the nerve distribution pattern of leg muscles in rat","volume":"88","author":"Peker","year":"2013","journal-title":"Anat. Sci. Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1097\/00005537-200311000-00022","article-title":"Three-dimensional reconstruction of immunolabeled neuromuscular junctions in the human thyroarytenoid muscle","volume":"113","author":"Sheppert","year":"2003","journal-title":"Laryngoscope"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Yi, K.H., Lee, H.J., Seo, K.K., and Kim, H.J. (2022). Intramuscular neural arborization of the latissimus dorsi muscle: Application of botulinum neurotoxin injection in flap reconstruction. Toxins, 14.","DOI":"10.3390\/toxins14020107"}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/5\/230\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:27:27Z","timestamp":1760030847000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/17\/5\/230"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5]]}},"alternative-id":["toxins17050230"],"URL":"https:\/\/doi.org\/10.3390\/toxins17050230","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}